echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Hutchison Whampoa Sofantinib's new indication will be approved soon

    Hutchison Whampoa Sofantinib's new indication will be approved soon

    • Last Update: 2021-06-23
    • Source: Internet
    • Author: User
    Tags

    future

    year

    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7th, Hutchison Whampoa Sofantinib's new indication for the market entered the approval stage and is expected to be approved in the near future


    On December 30 last year, Sofantinib was just approved for marketing for late-stage well-differentiated neuroendocrine tumors of non-pancreatic origin


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.